In the phase 3 CEPHEUS trial, patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma were treated with subcutaneous daratumumab plus bortezomib, lenalidomide and dexamethasone (D-VRd), which led to a significantly deeper and more durable increase in minimal residual disease responses compared with the control arm of VRd.
- Saad Z. Usmani
- Thierry Facon
- Sonja Zweegman
